bioRxiv · 10.1101/2025.07.28.667118
N-benzamides as Influenza Virus Fusion Inhibitors Acting on H1 and H5 Hemagglutinins
Abstract
Novel antiviral drugs are needed to prepare against infections from influenza A virus (IAV). Here a series of N-[(thiophen-3-yl)methylbenzamides which target the hemagglutinin (HA)-mediated fusion process is reported. The most active compound, VF-57a, displays a 50% effective concentration (EC50) of [~]0.8 M and antiviral selectivity index >130, in Madin-Darby canine kidney (MDCK) cells infected with A/H1N1 virus. VF-57a proved to be a strong inhibitor of A/H1N1- and A/H5N1-pseudovirus entry (EC50 values of 0.3 and 0.8 {micro}M, respectively). Cell-cell fusion assays in HA-expressing cells, surface plasmon resonance-based assessment of HA protein refolding, and resistance studies suggested that VF-57a prevents the conformational change of HA at acidic pH. Molecular modelling highlighted the role of the dimethylthiophene moiety and the amide-based tether in the anchoring to the binding cavity of HA. Our findings support further development of this class of IAV fusion inhibitors against A/H1N1 and A/H5N1 viruses.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Rimaux, S., Valdivia, A., Martin-Lopez, J., Francesconi, V., Escriche, C., Mestdagh, C., Van Berwaer, R., Schurmans, L., Verleye, K., Noppen, S., Lozano, O., Stevaert, A., Luque, F. J., Naesens, L., Vazquez, S.. 2025-07-28. N-benzamides as Influenza Virus Fusion Inhibitors Acting on H1 and H5 Hemagglutinins. https://doi.org/10.1101/2025.07.28.667118
Cite the original work for its findings. Save a collection to share your selection of sources.